Pamicell Publishes Gene Information in International Journal for Stem Cell Therapy Prediction Model Development

[Asia Economy Reporter Hyungsoo Park] Pharmicell is advancing to enhance the therapeutic effects using stem cells through the discovery of cardiovascular disease biomarkers.

Pharmicell announced on the 15th that the results of a study conducted with Professor Young Uh's team at Wonju Yonsei Medical Center, which discovered genetic information that can cause cardiovascular disease, i.e., cardiovascular disease biomarkers, were published in the international cell biology journal Cells.

This is an initial research result conducted to discover stem cell treatment response biomarkers. The genes of patients with cardiovascular disease and those of a control group without the disease were comparatively analyzed. Genes highly correlated with cardiovascular disease were identified. Pharmicell plans to utilize this to build a predictive model for stem cell therapeutics.

Biomarkers are indicators that can measure the progression of a disease or drug responsiveness through a person's genes. They enable early diagnosis before disease manifestation or prediction of therapeutic effects. Recently, as the development of personalized therapeutics using patients' own cells has become active, the importance of biomarkers that can predict treatment outcomes has increased.

Professor Taesik Lee of Wonju Severance Christian Hospital said, "Among the approximately 20,000 genes present in the body, candidate genes affecting cardiovascular disease were identified," adding, "By comparing the degree of improvement through the candidate gene panel in patients diagnosed with cardiovascular disease, the therapeutic effect can be quickly assessed."

A Pharmicell official explained, "We will not stop at developing therapeutics but will continue follow-up research to maximize therapeutic efficacy," and added, "We will continue biomarker discovery research to achieve the advancement and awareness improvement of stem cell therapeutics."

Pharmicell signed a joint research agreement with Wonju Yonsei Medical Center last January. Through this agreement, big data obtained from clinical trials is analyzed using artificial intelligence, and stem cell treatment response biomarkers are being discovered.